The young pharmaceutical company Nosopharm announced Tuesday it raised 2,4 million euros that will help develop a new class of antibiotics.
This sum was provided by the investment companies Auriga Partners, Kreaxi and Alto Invest "who join the company's historical shareholders," according to a statement.
The funds raised will enable Nosopharm to accelerate the preclinical development of its first antibiotic molecule, NOSO-95179, which targets Enterobacteriaceae, one of the pathogenic bacteria considered a priority by WHO.
The first clinical trials in humans should start running 2019, adds the company.
Created in Nîmes (Gard), Nosopharm is the result of a collaboration with the National Institute of Agricultural Research (INRA).